J&J exit from DES market with $600 million earnings hit and 1000 job losses
This article was originally published in Scrip
Johnson & Johnson subsidiary Cordis is planning to halt development of its investigational drug-eluting stent (DES) Nevo, as well as cease production of its already-marketed Cypher and Cypher Select Plus stents by the end of the year. The company will continue to sell its bare metal stents and said it was planning to focus on other cardiovascular therapies "where significant patient need exists".
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.